Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tal Schechter

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
Leukemia|February 6, 2020
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantMina D Aziz, Jay Shah, Urvi Kapoor, et al.
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.
Blood Advances|April 19, 2024
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHDAaron Etra, Najla El Jurdi, Nikolaos Katsivelos, et al.
Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.
Blood|February 13, 2020
Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studiesKirk R Schultz, Amina Kariminia, Bernard Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)Amar Gajjar, Giles W Robinson, Kyle S Smith, et al.
Blood Advances|August 15, 2025
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHDYu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Blood Advances|December 10, 2019
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host diseaseHrishikesh K Srinagesh, Umut Özbek, Urvi Kapoor, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Leukemia|February 6, 2020
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantMina D Aziz, Jay Shah, Urvi Kapoor, et al.
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.
Blood Advances|April 19, 2024
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHDAaron Etra, Najla El Jurdi, Nikolaos Katsivelos, et al.
Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.
Blood|February 13, 2020
Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studiesKirk R Schultz, Amina Kariminia, Bernard Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)Amar Gajjar, Giles W Robinson, Kyle S Smith, et al.
Blood Advances|August 15, 2025
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHDYu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Blood Advances|December 10, 2019
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host diseaseHrishikesh K Srinagesh, Umut Özbek, Urvi Kapoor, et al.
Pageof 15